HP
VRTX icon

Havemeyer Place’s Vertex Pharmaceuticals VRTX Stock Holding History

Havemeyer Place’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.53M Buy
5,655
+3,598
+175% +$1.68M 0.29% 102
2025
Q4 		$933K Buy
+2,057
New +$887K 0.18% 201

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Havemeyer Place's VRTX Position: Q1 2026 in Review

Havemeyer Place increased its Vertex Pharmaceuticals (VRTX) stake by 175% in Q1 2026, buying an estimated $1.68M and bringing the position to 5,655 shares worth $2.53M. The position accounts for 0.29% of the portfolio, ranked #102.

Havemeyer Place first reported a position in VRTX in Q4 2025 and has held it in 2 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Havemeyer Place held 5,655 shares of Vertex Pharmaceuticals worth $2.53M as of Q1 2026.
  • Havemeyer Place bought 3,598 Vertex Pharmaceuticals shares in Q1 2026, an estimated $1.68M.
  • Vertex Pharmaceuticals made up 0.29% of Havemeyer Place's portfolio in Q1 2026, its #102 holding.
  • Havemeyer Place first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Havemeyer Place's 13F filing for Q1 2026, filed 13 May 2026.